Corrigendum to PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study Volume 14, Issue 3, May-June 2020, Pages 322-330.e5.

Daniels, Stephen; Caprio, Sonia; Chaudhari, Umesh; Manvelian, Garen; Baccara-Dinet, Marie T; Brunet, Aurelie; Scemama, Michel; Loizeau, Virginie; Bruckert, Eric

Daniels, Stephen; Caprio, Sonia; Chaudhari, Umesh; Manvelian, Garen; Baccara-Dinet, Marie T; Brunet, Aurelie; Scemama, Michel; Loizeau, Virginie; Bruckert, Eric.

Afiliação

Daniels S; University of Colorado School of Medicine, Aurora, CO, USA. Electronic address: Stephen.Daniels@childrenscolorado.org.
Caprio S; Yale Pediatric Endocrinology, New Haven, CT, USA.
Chaudhari U; Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA.
Manvelian G; Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA.
Baccara-Dinet MT; Sanofi, Montpellier, France.
Brunet A; Sanofi, Montpellier, France.
Scemama M; Sanofi, Chilly-Mazarin, France.
Loizeau V; Sanofi, Chilly-Mazarin, France.
Bruckert E; Hôpital Pitié Salpêtrière, Paris, France; Institute of Cardiometabolism and Nutrition, Paris, France.

J Clin Lipidol ; 14(5): 741, 2020.

Article em En | MEDLINE | ID: mdl-33138961

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Clin Lipidol Assunto da revista: BIOQUIMICA / METABOLISMO Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google